Northern Trust Corp Cellectis S.A. Transaction History

Northern Trust Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$18.19 - $33.25 $278,925 - $509,855	-15,334 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$15.87 - $31.64 $7,078 - $14,111	-446 Reduced 2.83%	15,334 $415,000
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $722 - $958	-46 Reduced 0.29%	15,780 $292,000
Q2 2020 Aug 14, 2020	SELL	$8.21 - $21.02 $8,702 - $22,281	-1,060 Reduced 6.28%	15,826 $282,000
Q1 2020 May 14, 2020	SELL	$7.81 - $18.82 $6,302 - $15,187	-807 Reduced 4.56%	16,886 $155,000
Q4 2019 Feb 14, 2020	SELL	$9.73 - $19.31 $982 - $1,950	-101 Reduced 0.57%	17,693 $303,000
Q3 2019 Nov 13, 2019	BUY	$10.15 - $16.89 $162 - $270	16 Added 0.09%	17,794 $185,000
Q2 2019 Aug 13, 2019	BUY	$14.6 - $20.6 $1,547 - $2,183	106 Added 0.6%	17,778 $277,000
Q1 2019 May 13, 2019	SELL	$15.53 - $19.75 $5,885 - $7,485	-379 Reduced 2.1%	17,672 $324,000
Q4 2018 Feb 12, 2019	BUY	$15.58 - $28.41 $281,234 - $512,828	18,051 New	18,051 $301,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $86M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.